KALA BIO, INC. Increase (Decrease) in Inventories
KALA BIO, INC. (KALA) reported Increase (Decrease) in Inventories of -$7.54 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2025-03-31
- KALA BIO, INC. increase (decrease) in inventories for the quarter ending 2023-12-31 was $0.00.
- KALA BIO, INC. increase (decrease) in inventories for the quarter ending 2023-09-30 was -$5.24M.
- KALA BIO, INC. increase (decrease) in inventories for the quarter ending 2023-06-30 was -$111.00K, a 107.82% decline year-over-year.
- KALA BIO, INC. increase (decrease) in inventories for the quarter ending 2023-03-31 was -$2.19M, a 1434.76% decline year-over-year.
- KALA BIO, INC. increase (decrease) in inventories for fiscal 2023 was -$7.54M.
- KALA BIO, INC. increase (decrease) in inventories for fiscal 2022 was -$1.71M, a 127.30% decline from fiscal 2021.
- KALA BIO, INC. increase (decrease) in inventories for fiscal 2021 was $6.26M, a 164.23% increase from fiscal 2020.
- KALA BIO, INC. increase (decrease) in inventories for fiscal 2020 was $2.37M, a 44.56% decline from fiscal 2019.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$5.24M derived: sum of 2 quarters · filed 2025-03-31 | -$5.36M derived: sum of 3 quarters · filed 2025-03-31 | -$7.54M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$5.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$5.36M derived: sum of 2 quarters · filed 2024-11-12 | -$7.54M 10-Q · filed 2024-11-12 | -$10.26M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$111.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$2.30M 10-Q · filed 2024-08-06 | -$5.02M derived: sum of 3 quarters · filed 2024-08-06 | -$5.59M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$2.19M 10-Q · filed 2024-05-14 | -$4.91M derived: sum of 2 quarters · filed 2024-05-14 | -$5.48M derived: sum of 3 quarters · filed 2024-05-14 | -$4.06M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$3.29M derived: sum of 2 quarters · filed 2024-03-29 | -$1.87M derived: sum of 3 quarters · filed 2024-03-29 | -$1.71M 10-K · filed 2024-03-29 |
| 2022-09-30 | -$573.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $847.00K derived: sum of 2 quarters · filed 2023-11-13 | $1.01M 10-Q · filed 2023-11-13 | $496.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $1.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $1.58M 10-Q · filed 2023-08-04 | $1.07M derived: sum of 3 quarters · filed 2023-08-04 | $2.45M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $164.00K 10-Q · filed 2023-05-09 | -$351.00K derived: sum of 2 quarters · filed 2023-05-09 | $1.03M derived: sum of 3 quarters · filed 2023-05-09 | $3.61M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$515.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $870.00K derived: sum of 2 quarters · filed 2023-03-03 | $3.45M derived: sum of 3 quarters · filed 2023-03-03 | $6.26M 10-K · filed 2023-03-03 |
| 2021-09-30 | $1.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $3.96M derived: sum of 2 quarters · filed 2022-11-08 | $6.77M 10-Q · filed 2022-11-08 | $7.72M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $2.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $5.39M 10-Q · filed 2022-08-11 | $6.33M derived: sum of 3 quarters · filed 2022-08-11 | $6.45M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $2.81M 10-Q · filed 2022-05-16 | $3.75M derived: sum of 2 quarters · filed 2022-05-16 | $3.87M derived: sum of 3 quarters · filed 2022-05-16 | $4.60M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $945.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $1.06M derived: sum of 2 quarters · filed 2022-03-29 | $1.79M derived: sum of 3 quarters · filed 2022-03-29 | $2.37M 10-K · filed 2022-03-29 |
| 2020-09-30 | $117.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $844.00K derived: sum of 2 quarters · filed 2021-11-15 | $1.42M 10-Q · filed 2021-11-15 | $1.31M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $727.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.31M 10-Q · filed 2021-08-05 | $1.20M derived: sum of 3 quarters · filed 2021-08-05 | $1.62M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $579.00K 10-Q · filed 2021-05-05 | $471.00K derived: sum of 2 quarters · filed 2021-05-05 | $895.00K derived: sum of 3 quarters · filed 2021-05-05 | $3.79M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | -$108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $316.00K derived: sum of 2 quarters · filed 2021-02-25 | $3.21M derived: sum of 3 quarters · filed 2021-02-25 | $4.27M 10-K · filed 2021-02-25 |
| 2019-09-30 | $424.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $3.32M derived: sum of 2 quarters · filed 2020-11-05 | $4.38M 10-Q · filed 2020-11-05 | $7.34M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $3.96M 10-Q · filed 2020-08-06 | $6.91M derived: sum of 3 quarters · filed 2020-08-06 | |
| 2019-03-31 | $1.06M 10-Q · filed 2020-05-07 | $4.01M derived: sum of 2 quarters · filed 2020-05-07 | ||
| 2018-12-31 | $2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $3.87M 10-K · filed 2020-02-12 | ||
| 2018-09-30 | $910.00K 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |